CA-TULA-TECHNOLOGY,-INC.
15.9.2021 09:02:12 CEST | Business Wire | Press release
Jacobs Vehicle Systems and Tula Technology have signed a cooperation agreement to accelerate the development of Jacobs Cylinder Deactivation® (CDA® ) valve actuation technology in conjunction with Tula’s Dynamic Skip Fire (DSF® ) control algorithms. The agreement builds on two years of research and development collaboration between the two companies to reduce nitrous oxide (NOX ) and carbon dioxide (CO2 ) emissions from medium and heavy-duty vehicles, helping to meet ever-tightening environmental regulations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005336/en/
“Jacobs Vehicle Systems and Tula Technology are both great companies with great technologies, and we’ve been even more effective working together,” said John Fuerst, senior vice president of technology and innovation at Tula. “This agreement will advance our capabilities to produce better CDA products and dDSF controls.”
Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s dDSF achieve greater emission reductions when combined. Low-load cycle performance was estimated with a well-calibrated powertrain simulation tool to accurately capture the low-load system operation and emissions. This system showed as much as a 5% decrease in CO2 and a 74% reduction in NOX emissions compared to the baseline technology.
“While CDA and dDSF are available to commercial powertrain manufacturers as separate systems, our experience indicates that integrating the two technologies delivers much greater benefit to today’s medium- and heavy-duty engines,” said Steve Ernest, vice president of engineering and business development at Jacobs Vehicle Systems. “We have been working with Tula for several years, and this formal agreement solidifies our relationship as we demonstrate the benefits of using CDA and dDSF in tandem. Our efforts will provide the marketplace with sought-after solutions to meet increasingly challenging emissions standards. The synergies created through multiple development projects will offer customers the best possible outcomes for reducing NOX and CO2 simultaneously.”
The agreement will allow technical development to expand the operating range at which emissions reductions can be achieved when the two technologies are combined. Jacobs and Tula also will explore opportunities for reduced NOX and CO2 emissions in off-road vehicles and equip a Class 8 demonstrator truck with both Jacobs’ CDA and Tula’s diesel DSF technologies for customers to experience firsthand.
About Jacobs Vehicle Systems
Jacobs Vehicle Systems is headquartered in Bloomfield, Conn., where it has a 25,000 square meter design, testing, and manufacturing facility, with support sites in Europe, Japan, and India as well as manufacturing facilities in Suzhou, China, and Brno, Czech Republic. Jake Brake® products are used by heavy and medium-duty diesel engine manufacturers globally. Registered to the ISO 14001 and IATF16949 standards, Jacobs Vehicle Systems is a leading producer of vehicle retarding and valve actuation technologies and can be found at jakebrake.com .
About Tula Technology, Inc.
Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom